Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Biotech
Geron secures 12-2 AdComm vote in favor of blood cancer drug
The biotech won over an FDA advisory committee and secured a 12 to 2 vote in its favor—triggering a surge in its share price.
Nick Paul Taylor
Mar 15, 2024 5:00am
Gilead ends blood cancer development of troubled CD47 med
Feb 7, 2024 10:59am
Cash-strapped Gamida steps up search for strategic alternatives
Jan 29, 2024 8:41am
Oncternal reports patient death in CAR-T dose-escalation study
Dec 28, 2023 10:52am
Galecto posts myelofibrosis data as search for savior continues
Dec 22, 2023 6:50am
MorphoSys fails secondary in blood cancer trial, sinking stock
Nov 21, 2023 5:52am